General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data
Phase 2: Establishment (weeks 5 to 12) Maintain your introduction concentration through the establishment phase
Mild, transient sedation, light-headedness, or nausea are the most common effects.Rapid or excessive infusions can disturb electrolytes or cause fluid overload, though this is rare with proper dosing and monitoring
Small adhesive bandages: Rarely needed, but useful if injection sites bleed slightly
Taking Capsules with Food: This is the most frequent error
These include: Kidney Disease : Individuals with compromised kidney function should be cautious, as glutathione is processed by the kidneys, and excess supplementation could lead to complications
.png)
